Gilead to Buy Cancer Drugmaker for $21 Billion
The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
Gilead Flies Into Cancer Therapy With Kite Deal
The $11.9 billion acquisition gives Gilead access to the oncology market as its hepatitis C drugs face declining sales.
Takeda Buys Ariad in $5.2B Cancer Drug Bet
The Japanese drug giant is paying a 75% premium for Ariad to "transform our global solid tumor franchise."